Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RC48 Combinations in Post-T-DXd HER2+ Breast Cancer
NCT07065435Phase 2Recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Jan 2024
- Primary completion
- Dec 2025
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of disitamab vedotin in HER2-positive metastatic breast cancer, sponsored by Jiangsu Provincial People's Hospital. Started Jan 2024; status: recruiting.
02
Drugs
disitamab vedotin
03
Conditions
HER2-positive metastatic breast cancer
Beyond the preview
Go deeper on NCT07065435.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07065435.